TY - JOUR
T1 - Oxidative Stress in Structural Valve Deterioration :
T2 - A Longitudinal Clinical Study
AU - Galiñanes, Manuel
AU - Casós, Kelly
AU - Blasco-Lucas, Arnau
AU - Permanyer, Eduard
AU - Máñez, Rafael
AU - Le Tourneau, Thierry
AU - Barquinero, Jordi
AU - Schwartz, Simon
AU - Bottio, Tomaso
AU - Roussel, Jean Christian
AU - Fellah-Hebia, Imen
AU - Sénage, Thomas
AU - Evangelista Masip, Arturo
AU - Badano, Luigi P.
AU - Ruiz-Majoral, Alejandro
AU - Galli, Cesare
AU - Padler-Karavani, Vered
AU - Soulillou, Jean-Paul
AU - Vidal Guitart, Xavier
AU - Cozzi, Emanuele
AU - Costa, Cristina
PY - 2022
Y1 - 2022
N2 - The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60-72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months' follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction
AB - The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60-72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months' follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction
KW - Oxidative stress
KW - Aortic valve
KW - Biological heart valves
KW - Transcatheter aortic valve implantation
KW - Structural valve deterioration
KW - Protein nitration
KW - Lipid peroxidation
UR - https://www.scopus.com/pages/publications/85141587173
U2 - 10.3390/biom12111606
DO - 10.3390/biom12111606
M3 - Article
C2 - 36358956
SN - 2218-273X
VL - 12
JO - Biomolecules
JF - Biomolecules
ER -